David Hanley
Corporate Officer/Principal chez NUVATION BIO INC.
Fortune : 43 680 $ au 31/03/2024
Profil
David C.
Hanley is currently the Chief Technical Operations Officer at Nuvation Bio, Inc. He previously worked as the Senior Director-Global Pharmaceutical Development at The Medicines Co. from 2011 to 2014, as the VP-Pharmaceutical Sciences & Technical Operations at Radius Health, Inc. from 2014 to 2018, and as the Senior VP & Head-Global Pharmaceutical Development at BioXcel Therapeutics, Inc. from 2018 to 2021.
Hanley holds a doctorate degree from the University of Utah and an undergraduate degree from Virginia Commonwealth University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 29/02/2024 | 12 000 ( 0,01% ) | 43 680 $ | 31/03/2024 |
Postes actifs de David Hanley
| Sociétés | Poste | Début |
|---|---|---|
| NUVATION BIO INC. | Corporate Officer/Principal | 01/06/2021 |
Anciens postes connus de David Hanley
| Sociétés | Poste | Fin |
|---|---|---|
| BIOXCEL THERAPEUTICS, INC. | Corporate Officer/Principal | 01/05/2021 |
| RADIUS HEALTH, INC. | Corporate Officer/Principal | 01/08/2018 |
| THE MEDICINES COMPANY | Corporate Officer/Principal | 01/08/2014 |
Formation de David Hanley
| University of Utah | Doctorate Degree |
| Virginia Commonwealth University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BIOXCEL THERAPEUTICS, INC. | Health Technology |
| NUVATION BIO INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
The Medicines Co.
 The Medicines Co. Pharmaceuticals: MajorHealth Technology The Medicines Co. is a biopharmaceutical company, which focuses on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on acute and intensive care hospitals worldwide. The firm markets its brands Angiomax, Cleviprex, injectable emulsion, Ionsys, Kengreal, Minocin for injection, and Orbactiv. The company was founded by Clive A. Meanwell, Helmut Giersiefen, John W. Villiger and T. Scott Johnson on July 31, 1996 and is headquartered in Parsippany, NJ. | Health Technology |
Radius Health, Inc.
 Radius Health, Inc. BiotechnologyHealth Technology Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. | Health Technology |
